You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePramipexole
Accession NumberDB00413  (APRD00156)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionPramipexole is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist.
Structure
Thumb
Synonyms
(-)-Pramipexole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-
Pramipexol
Pramipexole
Pramipexolum
External Identifiers
  • PNU 98528
  • SND 919 Cl 2Y
  • SUD 919 CL 24
  • U 98528 E
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PramipexoleTablet1.5 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet0.25 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet0.5 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Act PramipexoleTablet1.0 mgOralActavis Pharma Company2009-04-15Not applicableCanada
Auro-pramipexoleTablet0.5 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet1.5 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-pramipexoleTablet1 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet0.125 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-pramipexoleTablet0.25 mgOralAuro Pharma Inc2014-04-29Not applicableCanada
Ava-pramipexoleTablet0.25 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoleTablet0.5 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoleTablet1.0 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pramipexoleTablet1.5 mgOralAvanstra Inc2011-09-192014-08-21Canada
Dom-pramipexoleTablet0.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-pramipexoleTablet0.25 mgOralDominion Pharmacal2012-09-26Not applicableCanada
Dom-pramipexoleTablet1.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-pramipexoleTablet1.5 mgOralDominion PharmacalNot applicableNot applicableCanada
MirapexTablet.5 mg/1OralRebel Distributors Corp2004-01-01Not applicableUs
MirapexTablet1.0 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
MirapexTablet.75 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2007-10-01Not applicableUs
MirapexTablet.5 mg/1OralPhysicians Total Care, Inc.2005-09-12Not applicableUs
MirapexTablet0.125 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-09Not applicableCanada
MirapexTablet1 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
MirapexTablet.125 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-05Not applicableUs
MirapexTablet1.5 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
MirapexTablet.125 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
MirapexTablet1 mg/1OralPhysicians Total Care, Inc.2007-01-09Not applicableUs
MirapexTablet1.5 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
MirapexTablet.25 mg/1OralPhysicians Total Care, Inc.2007-03-23Not applicableUs
MirapexTablet0.5 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2000-03-17Not applicableCanada
MirapexTablet.25 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
MirapexTablet.25 mg/1OralCardinal Health2004-01-01Not applicableUs
MirapexTablet.125 mg/1OralPhysicians Total Care, Inc.2003-09-04Not applicableUs
MirapexTablet.5 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2004-01-01Not applicableUs
MirapexTablet0.25 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1998-02-26Not applicableCanada
Mirapex ERTablet, extended release.375 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERTablet, extended release.75 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERTablet, extended release1.5 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERTablet, extended release2.25 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2011-06-18Not applicableUs
Mirapex ERTablet, extended release3 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
Mirapex ERTablet, extended release3.75 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2011-06-18Not applicableUs
Mirapex ERTablet, extended release4.5 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2010-02-22Not applicableUs
MirapexinTablet0.35 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.18 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet1.1 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.18 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet1.1 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.7 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.088 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.35 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.7 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet0.088 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
MirapexinTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1998-02-23Not applicableEu
Mylan-pramipexoleTablet0.5 mgOralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoleTablet1 mgOralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoleTablet1.5 mgOralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Mylan-pramipexoleTablet0.25 mgOralMylan Pharmaceuticals Ulc2011-11-23Not applicableCanada
Ntp-pramipexoleTablet1.5 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoleTablet0.25 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoleTablet0.5 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pramipexoleTablet1.0 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Nu-pramipexoleTablet1.5 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-pramipexoleTablet0.25 mgOralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoleTablet0.50 mgOralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoleTablet1.0 mgOralPharmascience Inc2006-12-29Not applicableCanada
PMS-pramipexoleTablet1.5 mgOralPharmascience Inc2006-12-29Not applicableCanada
PramipexoleTablet0.25 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
PramipexoleTablet0.5 mgOralSanis Health Inc2011-07-21Not applicableCanada
PramipexoleTablet0.50 mgOralPro Doc Limitee2009-06-15Not applicableCanada
PramipexoleTablet1 mgOralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
PramipexoleTablet1 mgOralSanis Health Inc2011-07-21Not applicableCanada
PramipexoleTablet0.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
PramipexoleTablet1.0 mgOralPro Doc Limitee2009-06-15Not applicableCanada
PramipexoleTablet1.5 mgOralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
PramipexoleTablet1.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
PramipexoleTablet0.25 mgOralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
PramipexoleTablet1.5 mgOralSanis Health Inc2011-07-21Not applicableCanada
PramipexoleTablet1.5 mgOralPro Doc Limitee2009-06-15Not applicableCanada
PramipexoleTablet0.25 mgOralPro Doc Limitee2009-06-15Not applicableCanada
PramipexoleTablet1.5 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
PramipexoleTablet0.5 mgOralSivem Pharmaceuticals Ulc2009-04-09Not applicableCanada
PramipexoleTablet0.25 mgOralSanis Health Inc2011-07-21Not applicableCanada
Sandoz PramipexoleTablet0.5 mgOralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz PramipexoleTablet1.0 mgOralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz PramipexoleTablet1.5 mgOralSandoz Canada Incorporated2008-08-14Not applicableCanada
Sandoz PramipexoleTablet0.25 mgOralSandoz Canada Incorporated2008-08-14Not applicableCanada
SifrolTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.35 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.088 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.7 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.35 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.18 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet1.1 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.18 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.05 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release3.15 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet1.1 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.26 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release1.57 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.7 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.1 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release2.62 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet0.088 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
SifrolTablet, extended release0.52 mgOralBoehringer Ingelheim International Gmb H1997-10-14Not applicableEu
Teva-pramipexoleTablet0.5 mgOralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoleTablet1.0 mgOralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoleTablet1.5 mgOralTeva Canada Limited2006-12-07Not applicableCanada
Teva-pramipexoleTablet0.25 mgOralTeva Canada Limited2006-12-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pramipexoleTablet0.5 mgOralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoleTablet0.75 mgOralApotex IncNot applicableNot applicableCanada
Apo-pramipexoleTablet1.0 mgOralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoleTablet1.5 mgOralApotex Inc2007-02-26Not applicableCanada
Apo-pramipexoleTablet0.125 mgOralApotex IncNot applicableNot applicableCanada
Apo-pramipexoleTablet0.25 mgOralApotex Inc2007-02-26Not applicableCanada
PramipexoleTablet1 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet.5 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet1 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.125 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.125 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet1.5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet.75 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet1.5 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.25 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet.125 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet.75 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet1 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet.5 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
PramipexoleTablet.5 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-23Not applicableUs
PramipexoleTablet.25 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet1.5 mg/1OralCamber Pharmaceuticals, Inc.2015-08-01Not applicableUs
PramipexoleTablet.75 mg/1OralAv Kare, Inc.2016-07-27Not applicableUs
Pramipexole AccordTablet0.35 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.088 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet1.1 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.35 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.088 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet1.1 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.7 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.18 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.7 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole AccordTablet0.18 mgOralAccord Healthcare Ltd2011-09-30Not applicableEu
Pramipexole DihydrochlorideTablet.125 mg/1OralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release4.5 mg/1OralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release1.5 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralA S Medication Solutions2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1Oralbryant ranch prepack2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralKAISER FOUNDATION HOSPITALS2011-02-15Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralSTAT Rx USA LLC2010-01-01Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralPhysicians Total Care, Inc.2010-08-23Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralSandoz Inc2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole DihydrochlorideTablet.25 mg/1OralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralA S Medication Solutions2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralAmerican Health Packaging2011-05-01Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet, extended release.75 mg/1OralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release2.25 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralA S Medication Solutions2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralPhysicians Total Care, Inc.2011-04-08Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralSandoz Inc2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole DihydrochlorideTablet.5 mg/1OralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-01Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet, extended release1.5 mg/1OralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet, extended release.375 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralA S Medication Solutions2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1Oralbryant ranch prepack2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralAmerican Health Packaging2014-07-31Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole DihydrochlorideTablet.125 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release3 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralCardinal Health2011-05-01Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralSandoz Inc2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralGlenmark Pharmaceuticals Inc., Usa2016-01-31Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralA S Medication Solutions2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralPhysicians Total Care, Inc.2010-04-20Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole DihydrochlorideTablet1 mg/1OralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralSandoz Inc2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet, extended release3 mg/1OralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release.75 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralA S Medication Solutions2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1Oralbryant ranch prepack2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralStrides Arcolab Limited2014-06-17Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralBreckenridge Pharmaceutical, Inc.2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralQualitest Pharmaceuticals2013-07-152016-01-20Us
Pramipexole DihydrochlorideTablet.125 mg/1OralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralVensun Pharmaceuticals, Inc.2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralWatson Pharma, Inc.2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralAurobindo Pharma Limited2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet, extended release4.5 mg/1OralMacleods Pharmaceuticals Limited2016-06-24Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralMacleods Pharmaceuticals Limited2012-09-21Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralA S Medication Solutions2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-10-09Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralAv Kare, Inc.2013-09-05Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralCardinal Health2010-11-17Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralSandoz Inc2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralMylan Pharmaceuticals Inc.2010-11-04Not applicableUs
Pramipexole DihydrochlorideTablet, extended release.375 mg/1OralDr. Reddy's Laboratories Limited2015-08-14Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralA S Medication Solutions2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.25 mg/1OralSandoz Inc2010-07-06Not applicableUs
Pramipexole DihydrochlorideTablet1 mg/1OralCarilion Materials Management2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralCitron Pharma LLC2012-10-26Not applicableUs
Pramipexole DihydrochlorideTablet.125 mg/1OralCadila Healthcare Limited2010-07-10Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralPhysicians Total Care, Inc.2010-05-03Not applicableUs
Pramipexole DihydrochlorideTablet1.5 mg/1OralGolden State Medical Supply, Inc2014-10-29Not applicableUs
Pramipexole DihydrochlorideTablet.75 mg/1OralTorrent Pharmaceuticals Limited2010-10-08Not applicableUs
Pramipexole DihydrochlorideTablet.5 mg/1OralScie Gen Pharmaceuticals Inc2014-10-29Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release3 mg/1OralPar Pharmaceutical, Inc.2015-07-20Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release1.5 mg/1OralAv Kare, Inc.2016-11-23Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release3.75 mg/1OralPar Pharmaceutical, Inc.2016-07-05Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release.375 mg/1OralPar Pharmaceutical, Inc.2015-04-22Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release2.25 mg/1OralPar Pharmaceutical, Inc.2015-11-20Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release3 mg/1OralAv Kare, Inc.2016-11-23Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release.75 mg/1OralPar Pharmaceutical, Inc.2015-02-09Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release4.5 mg/1OralAv Kare, Inc.2016-07-05Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release1.5 mg/1OralPar Pharmaceutical, Inc.2015-02-09Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release4.5 mg/1OralPar Pharmaceutical, Inc.2016-07-05Not applicableUs
Pramipexole Dihydrochloride Extended-releaseTablet, extended release.75 mg/1OralAv Kare, Inc.2016-11-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GleparkGlenmark
MedopexolMedochemie
MiramelClonmel
MiraperSpecifar
MirapexinBoehringer Ingelheim
PexolaBoehringer Ingelheim
SifrolBoehringer Ingelheim
Sifrol ERBoehringer Ingelheim
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pramipexole dihydrochloride monohydrate
ThumbNot applicableDBSALT001198
Pramipexole hydrochloride
104632-25-9
Thumb
  • InChI Key: QMNWXHSYPXQFSK-KLXURFKVSA-N
  • Monoisotopic Mass: 283.067673727
  • Average Mass: 284.249
DBSALT000143
Categories
UNII83619PEU5T
CAS number104632-26-0
WeightAverage: 211.327
Monoisotopic: 211.114318249
Chemical FormulaC10H17N3S
InChI KeyFASDKYOPVNHBLU-ZETCQYMHSA-N
InChI
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
IUPAC Name
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
SMILES
CCCN[[email protected]]1CCC2=C(C1)SC(N)=N2
Pharmacology
IndicationFor the treatment of signs and symptoms of idiopathic Parkinson's disease
Structured Indications
PharmacodynamicsPramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.
Mechanism of actionThe precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(3) dopamine receptorProteinyes
agonist
HumanP35462 details
D(2) dopamine receptorProteinyes
agonist
HumanP14416 details
D(4) dopamine receptorProteinyes
agonist
HumanP21917 details
Alpha-2B adrenergic receptorProteinunknown
unknown
HumanP18089 details
5-hydroxytryptamine receptor 1AProteinunknown
unknown
HumanP08908 details
5-hydroxytryptamine receptor 1DProteinunknown
unknown
HumanP28221 details
Alpha-2A adrenergic receptorProteinunknown
partial agonist
HumanP08913 details
5-hydroxytryptamine receptor 1BProteinunknown
unknown
HumanP28222 details
5-hydroxytryptamine receptor 2AProteinunknown
unknown
HumanP28223 details
5-hydroxytryptamine receptor 2BProteinunknown
unknown
HumanP41595 details
5-hydroxytryptamine receptor 2CProteinunknown
unknown
HumanP28335 details
Alpha-2C adrenergic receptorProteinunknown
unknown
HumanP18825 details
D(1A) dopamine receptorProteinunknown
unknown
HumanP21728 details
D(1B) dopamine receptorProteinunknown
unknown
HumanP21918 details
Related Articles
AbsorptionRapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
Volume of distribution
  • 500 L
Protein bindingAbout 15% bound to plasma proteins.
Metabolism

No metabolites have been identified in plasma or urine.

Route of eliminationUrinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
Half life8 hours
Clearance
  • renal cl=400 mL/min
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the sedative activities of Pramipexole.Investigational
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Pramipexole.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pramipexole.Approved
AcepromazineAcepromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Pramipexole.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Pramipexole is combined with Acetazolamide.Approved, Vet Approved
adipiplonadipiplon may increase the sedative activities of Pramipexole.Investigational
AgomelatineAgomelatine may increase the sedative activities of Pramipexole.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pramipexole.Approved
AlfaxaloneAlfaxalone may increase the sedative activities of Pramipexole.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Pramipexole.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Pramipexole.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Pramipexole.Experimental, Illicit
AlprazolamAlprazolam may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Pramipexole.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Pramipexole.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pramipexole.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Pramipexole.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Pramipexole.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Pramipexole.Approved
AmobarbitalAmobarbital may increase the sedative activities of Pramipexole.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Pramipexole.Approved
AmperozideAmperozide may increase the sedative activities of Pramipexole.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pramipexole.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Pramipexole.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Pramipexole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Pramipexole.Approved
AripiprazoleAripiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pramipexole.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pramipexole.Approved, Investigational
ArticaineArticaine may increase the sedative activities of Pramipexole.Approved
AsenapineAsenapine may increase the sedative activities of Pramipexole.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Pramipexole.Approved
AzaperoneAzaperone may increase the sedative activities of Pramipexole.Vet Approved
AzelastineAzelastine may increase the sedative activities of Pramipexole.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pramipexole.Approved
BaclofenBaclofen may increase the sedative activities of Pramipexole.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Pramipexole.Experimental
BarbitalBarbital may increase the sedative activities of Pramipexole.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pramipexole.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pramipexole.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Pramipexole.Approved
BenperidolBenperidol may increase the sedative activities of Pramipexole.Investigational
BenzocaineBenzocaine may increase the sedative activities of Pramipexole.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Pramipexole.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pramipexole.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pramipexole.Approved
BlonanserinThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Blonanserin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Pramipexole.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Pramipexole.Approved
BrimonidineBrimonidine may increase the sedative activities of Pramipexole.Approved
BromazepamBromazepam may increase the sedative activities of Pramipexole.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramipexole.Approved, Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Pramipexole.Approved
BrotizolamBrotizolam may increase the sedative activities of Pramipexole.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Pramipexole.Approved
BupivacaineBupivacaine may increase the sedative activities of Pramipexole.Approved, Investigational
BuprenorphineBuprenorphine may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Pramipexole can be increased when it is combined with Bupropion.Approved
BuspironeBuspirone may increase the sedative activities of Pramipexole.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Pramipexole.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Pramipexole.Vet Approved
ButalbitalButalbital may increase the sedative activities of Pramipexole.Approved, Illicit
ButambenButamben may increase the sedative activities of Pramipexole.Approved
ButethalButethal may increase the sedative activities of Pramipexole.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Pramipexole.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pramipexole.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pramipexole.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Pramipexole.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pramipexole.Approved
CarbinoxamineCarbinoxamine may increase the sedative activities of Pramipexole.Approved
CarfentanilCarfentanil may increase the sedative activities of Pramipexole.Illicit, Vet Approved
CariprazineThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Pramipexole.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Pramipexole.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Pramipexole.Approved, Investigational
CetirizineCetirizine may increase the sedative activities of Pramipexole.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Pramipexole.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Pramipexole.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Pramipexole.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pramipexole.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the sedative activities of Pramipexole.Approved
ChlorpromazineChlorpromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Pramipexole.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Pramipexole.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Pramipexole.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pramipexole.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pramipexole.Approved
CimetidineThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.Approved
CinchocaineCinchocaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ClemastineClemastine may increase the sedative activities of Pramipexole.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pramipexole.Approved
ClidiniumClidinium may increase the sedative activities of Pramipexole.Approved
ClobazamClobazam may increase the sedative activities of Pramipexole.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Pramipexole.Approved, Investigational
clomethiazoleclomethiazole may increase the sedative activities of Pramipexole.Investigational
ClomipramineClomipramine may increase the sedative activities of Pramipexole.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Pramipexole.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Pramipexole.Approved
ClorazepateClorazepate may increase the sedative activities of Pramipexole.Approved, Illicit
ClozapineClozapine may increase the sedative activities of Pramipexole.Approved
CocaineCocaine may increase the sedative activities of Pramipexole.Approved, Illicit
CodeineCodeine may increase the sedative activities of Pramipexole.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pramipexole.Approved, Investigational
CyclizineCyclizine may increase the sedative activities of Pramipexole.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Pramipexole.Approved
CyproheptadineCyproheptadine may increase the sedative activities of Pramipexole.Approved
DantroleneDantrolene may increase the sedative activities of Pramipexole.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Pramipexole.Approved
DapiprazoleDapiprazole may increase the sedative activities of Pramipexole.Approved
deramciclanederamciclane may increase the sedative activities of Pramipexole.Investigational
DesfluraneDesflurane may increase the sedative activities of Pramipexole.Approved
DesipramineDesipramine may increase the sedative activities of Pramipexole.Approved
DesloratadineDesloratadine may increase the sedative activities of Pramipexole.Approved, Investigational
DetomidineDetomidine may increase the sedative activities of Pramipexole.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Pramipexole.Approved
DexmedetomidineDexmedetomidine may increase the sedative activities of Pramipexole.Approved, Vet Approved
DextromoramideDextromoramide may increase the sedative activities of Pramipexole.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
DezocineDezocine may increase the sedative activities of Pramipexole.Approved
DiazepamDiazepam may increase the sedative activities of Pramipexole.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Pramipexole.Approved
DifenoxinDifenoxin may increase the sedative activities of Pramipexole.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the sedative activities of Pramipexole.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the sedative activities of Pramipexole.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Pramipexole.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Pramipexole.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Pramipexole.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Pramipexole.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Pramipexole.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Pramipexole.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Pramipexole.Approved
DoramectinDoramectin may increase the sedative activities of Pramipexole.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Pramipexole.Approved
DoxepinDoxepin may increase the sedative activities of Pramipexole.Approved
DoxylamineDoxylamine may increase the sedative activities of Pramipexole.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Pramipexole.Investigational
DroperidolDroperidol may increase the sedative activities of Pramipexole.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Pramipexole.Experimental, Illicit
DuloxetinePramipexole may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Pramipexole.Approved
EcgonineEcgonine may increase the sedative activities of Pramipexole.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the sedative activities of Pramipexole.Experimental
EcopipamEcopipam may increase the sedative activities of Pramipexole.Investigational
EfavirenzEfavirenz may increase the sedative activities of Pramipexole.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pramipexole.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Pramipexole.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pramipexole.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole.Approved
EnfluraneEnflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Pramipexole.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Pramipexole.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pramipexole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pramipexole.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Pramipexole.Approved
EstazolamEstazolam may increase the sedative activities of Pramipexole.Approved, Illicit
EszopicloneEszopiclone may increase the sedative activities of Pramipexole.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pramipexole.Approved
EthanolEthanol may increase the sedative activities of Pramipexole.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the sedative activities of Pramipexole.Approved
EthotoinEthotoin may increase the sedative activities of Pramipexole.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Pramipexole.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Pramipexole.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Pramipexole.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Pramipexole.Approved
EtifoxineEtifoxine may increase the sedative activities of Pramipexole.Withdrawn
EtizolamEtizolam may increase the sedative activities of Pramipexole.Approved
EtomidateEtomidate may increase the sedative activities of Pramipexole.Approved
EtorphineEtorphine may increase the sedative activities of Pramipexole.Illicit, Vet Approved
EzogabineEzogabine may increase the sedative activities of Pramipexole.Approved
FelbamateFelbamate may increase the sedative activities of Pramipexole.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Pramipexole.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pramipexole.Approved
FentanylFentanyl may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the sedative activities of Pramipexole.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pramipexole.Approved
FlibanserinFlibanserin may increase the sedative activities of Pramipexole.Approved
FludiazepamFludiazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Pramipexole.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FlupentixolFlupentixol may increase the sedative activities of Pramipexole.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Pramipexole.Approved
FlurazepamFlurazepam may increase the sedative activities of Pramipexole.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Pramipexole.Approved
Fluticasone PropionateFluticasone Propionate may increase the sedative activities of Pramipexole.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Pramipexole.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pramipexole.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Pramipexole.Approved
FospropofolFospropofol may increase the sedative activities of Pramipexole.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Pramipexole.Approved, Vet Approved
GabapentinGabapentin may increase the sedative activities of Pramipexole.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the sedative activities of Pramipexole.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Pramipexole.Approved, Illicit
GepironeGepirone may increase the sedative activities of Pramipexole.Investigational
GlutethimideGlutethimide may increase the sedative activities of Pramipexole.Approved, Illicit
GuanfacineGuanfacine may increase the sedative activities of Pramipexole.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Pramipexole.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Pramipexole.Approved
HalothaneHalothane may increase the sedative activities of Pramipexole.Approved, Vet Approved
HeroinHeroin may increase the sedative activities of Pramipexole.Approved, Illicit
HexobarbitalHexobarbital may increase the sedative activities of Pramipexole.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Pramipexole.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Pramipexole.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Pramipexole.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pramipexole.Approved
HydromorphoneHydromorphone may increase the sedative activities of Pramipexole.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Pramipexole.Approved
IloperidoneIloperidone may increase the sedative activities of Pramipexole.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Pramipexole.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pramipexole.Investigational
ImipramineImipramine may increase the sedative activities of Pramipexole.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Pramipexole.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Pramipexole.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pramipexole.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pramipexole.Approved
IsofluraneIsoflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Pramipexole.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Pramipexole.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Pramipexole.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Pramipexole.Approved
KetamineKetamine may increase the sedative activities of Pramipexole.Approved, Vet Approved
KetazolamKetazolam may increase the sedative activities of Pramipexole.Approved
KetobemidoneKetobemidone may increase the sedative activities of Pramipexole.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Pramipexole.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pramipexole.Approved
LamotrigineLamotrigine may increase the sedative activities of Pramipexole.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pramipexole.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Pramipexole.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Pramipexole.Approved
LevobupivacaineLevobupivacaine may increase the sedative activities of Pramipexole.Approved
LevocabastineLevocabastine may increase the sedative activities of Pramipexole.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Pramipexole.Approved
LevodopaLevodopa may increase the sedative activities of Pramipexole.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Pramipexole.Approved
LevorphanolLevorphanol may increase the sedative activities of Pramipexole.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Pramipexole.Approved, Investigational
LidocaineLidocaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pramipexole.Approved, Investigational
LithiumLithium may increase the sedative activities of Pramipexole.Approved
LofentanilLofentanil may increase the sedative activities of Pramipexole.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Pramipexole.Approved, Investigational
LoratadineLoratadine may increase the sedative activities of Pramipexole.Approved
LorazepamLorazepam may increase the sedative activities of Pramipexole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pramipexole.Approved
LoxapineLoxapine may increase the sedative activities of Pramipexole.Approved
Lu AA21004Lu AA21004 may increase the sedative activities of Pramipexole.Investigational
LumateperoneThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Lumateperone.Investigational
LurasidoneLurasidone may increase the sedative activities of Pramipexole.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Pramipexole.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Pramipexole.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Pramipexole.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pramipexole.Approved
MeclizineMeclizine may increase the sedative activities of Pramipexole.Approved
MedetomidineMedetomidine may increase the sedative activities of Pramipexole.Vet Approved
MelatoninMelatonin may increase the sedative activities of Pramipexole.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Pramipexole.Approved
MepivacaineMepivacaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Pramipexole.Approved, Illicit
MesoridazineMesoridazine may increase the sedative activities of Pramipexole.Approved
MetaxaloneMetaxalone may increase the sedative activities of Pramipexole.Approved
MethadoneMethadone may increase the sedative activities of Pramipexole.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Pramipexole.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Pramipexole.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Pramipexole.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Pramipexole.Approved
MethocarbamolMethocarbamol may increase the sedative activities of Pramipexole.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Pramipexole.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Pramipexole.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Pramipexole.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Pramipexole.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Pramipexole.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Pramipexole.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pramipexole.Approved
MetoclopramideThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Pramipexole.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Pramipexole.Approved, Investigational
MidazolamMidazolam may increase the sedative activities of Pramipexole.Approved, Illicit
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Pramipexole.Approved
MirtazapineMirtazapine may increase the sedative activities of Pramipexole.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pramipexole.Approved
MolindoneMolindone may increase the sedative activities of Pramipexole.Approved
MorphineMorphine may increase the sedative activities of Pramipexole.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Pramipexole.Approved
NabiloneNabilone may increase the sedative activities of Pramipexole.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Pramipexole.Approved
NalbuphineNalbuphine may increase the sedative activities of Pramipexole.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Pramipexole.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Pramipexole.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Pramipexole.Approved
NicorandilNicorandil may increase the hypotensive activities of Pramipexole.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Pramipexole.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pramipexole.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Pramipexole.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Pramipexole.Approved
NitrazepamNitrazepam may increase the sedative activities of Pramipexole.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pramipexole.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Pramipexole.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pramipexole.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Pramipexole.Approved, Vet Approved
NormethadoneNormethadone may increase the sedative activities of Pramipexole.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Pramipexole.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pramipexole.Approved
OlanzapineOlanzapine may increase the sedative activities of Pramipexole.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pramipexole.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Pramipexole.Approved
OndansetronOndansetron may increase the sedative activities of Pramipexole.Approved
OpiumOpium may increase the sedative activities of Pramipexole.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Pramipexole.Approved
OsanetantOsanetant may increase the sedative activities of Pramipexole.Investigational
OxazepamOxazepam may increase the sedative activities of Pramipexole.Approved
OxetacaineOxetacaine may increase the sedative activities of Pramipexole.Investigational
OxprenololOxprenolol may increase the sedative activities of Pramipexole.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Pramipexole.Approved
OxycodoneOxycodone may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pramipexole.Approved, Vet Approved
PaliperidonePaliperidone may increase the sedative activities of Pramipexole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Pramipexole.Approved
ParaldehydeParaldehyde may increase the sedative activities of Pramipexole.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Pramipexole.Approved, Investigational
PentazocinePentazocine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Pramipexole.Approved, Vet Approved
PerampanelPerampanel may increase the sedative activities of Pramipexole.Approved
PerazinePerazine may increase the sedative activities of Pramipexole.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pramipexole.Approved
PerospironePerospirone may increase the sedative activities of Pramipexole.Approved
PerphenazinePerphenazine may increase the sedative activities of Pramipexole.Approved
PethidinePethidine may increase the sedative activities of Pramipexole.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pramipexole.Approved
PhenobarbitalPhenobarbital may increase the sedative activities of Pramipexole.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pramipexole.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Pramipexole.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Pramipexole.Approved
PhenytoinPhenytoin may increase the sedative activities of Pramipexole.Approved, Vet Approved
PimavanserinThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Pimavanserin.Investigational
PimozidePimozide may increase the sedative activities of Pramipexole.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Pramipexole.Approved
PipamperonePipamperone may increase the sedative activities of Pramipexole.Approved
PipotiazinePipotiazine may increase the sedative activities of Pramipexole.Approved
PiritramidePiritramide may increase the sedative activities of Pramipexole.Investigational
PizotifenPizotifen may increase the sedative activities of Pramipexole.Approved
PomalidomidePomalidomide may increase the sedative activities of Pramipexole.Approved
PramocainePramocaine may increase the sedative activities of Pramipexole.Approved
PrazepamPrazepam may increase the sedative activities of Pramipexole.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Pramipexole.Approved
PregabalinPregabalin may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the sedative activities of Pramipexole.Investigational
PrilocainePrilocaine may increase the sedative activities of Pramipexole.Approved
PrimidonePrimidone may increase the sedative activities of Pramipexole.Approved, Vet Approved
ProcaineProcaine may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PromazinePromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PromethazinePromethazine may increase the sedative activities of Pramipexole.Approved
ProparacaineProparacaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Pramipexole.Approved
PropofolPropofol may increase the sedative activities of Pramipexole.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Pramipexole.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Pramipexole.Approved, Investigational
ProtriptylineProtriptyline may increase the sedative activities of Pramipexole.Approved
PSD502PSD502 may increase the sedative activities of Pramipexole.Investigational
QuazepamQuazepam may increase the sedative activities of Pramipexole.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Pramipexole.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pramipexole.Approved, Investigational
RacloprideRaclopride may increase the sedative activities of Pramipexole.Investigational
RamelteonRamelteon may increase the sedative activities of Pramipexole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pramipexole.Approved
RasagilineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the sedative activities of Pramipexole.Approved
RemoxiprideRemoxipride may increase the sedative activities of Pramipexole.Approved, Withdrawn
ReserpineReserpine may increase the sedative activities of Pramipexole.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Pramipexole.Approved
RisperidoneRisperidone may increase the sedative activities of Pramipexole.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Pramipexole.Investigational
RomifidineRomifidine may increase the sedative activities of Pramipexole.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the sedative activities of Pramipexole.Approved
RotigotineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rotigotine.Approved
RP5063The therapeutic efficacy of Pramipexole can be decreased when used in combination with RP5063.Investigational
S-EthylisothioureaS-Ethylisothiourea may increase the sedative activities of Pramipexole.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sacubitril.Approved
Sage 547Sage 547 may increase the sedative activities of Pramipexole.Investigational
ScopolamineScopolamine may increase the sedative activities of Pramipexole.Approved
SecobarbitalSecobarbital may increase the sedative activities of Pramipexole.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may increase the sedative activities of Pramipexole.Approved, Withdrawn
SevofluraneSevoflurane may increase the sedative activities of Pramipexole.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Pramipexole is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the sedative activities of Pramipexole.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Pramipexole.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Pramipexole.Approved
StiripentolStiripentol may increase the sedative activities of Pramipexole.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Pramipexole is combined with Streptokinase.Approved
SufentanilSufentanil may increase the sedative activities of Pramipexole.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pramipexole.Approved
SuvorexantSuvorexant may increase the sedative activities of Pramipexole.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tamsulosin.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Pramipexole.Investigational
TapentadolTapentadol may increase the sedative activities of Pramipexole.Approved
TasimelteonTasimelteon may increase the sedative activities of Pramipexole.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pramipexole.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Pramipexole.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Pramipexole.Approved
TetrabenazineTetrabenazine may increase the sedative activities of Pramipexole.Approved
TetracaineTetracaine may increase the sedative activities of Pramipexole.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the sedative activities of Pramipexole.Investigational
ThalidomideThalidomide may increase the sedative activities of Pramipexole.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the sedative activities of Pramipexole.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Pramipexole.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Pramipexole.Approved
ThioridazineThioridazine may increase the sedative activities of Pramipexole.Approved
ThiothixeneThiothixene may increase the sedative activities of Pramipexole.Approved
TiagabineTiagabine may increase the sedative activities of Pramipexole.Approved
TiaprideTiapride may increase the sedative activities of Pramipexole.Investigational
TiletamineTiletamine may increase the sedative activities of Pramipexole.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Pramipexole.Approved
TizanidineTizanidine may increase the sedative activities of Pramipexole.Approved
TolazolineThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tolazoline.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Pramipexole.Approved, Withdrawn
TopiramateTopiramate may increase the sedative activities of Pramipexole.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Pramipexole.Approved
TramadolTramadol may increase the sedative activities of Pramipexole.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pramipexole.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Pramipexole.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Pramipexole.Approved
TrazodoneTrazodone may increase the sedative activities of Pramipexole.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pramipexole is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Pramipexole.Approved
TriazolamTriazolam may increase the sedative activities of Pramipexole.Approved
TrifluoperazineTrifluoperazine may increase the sedative activities of Pramipexole.Approved
TriflupromazineTriflupromazine may increase the sedative activities of Pramipexole.Approved, Vet Approved
TrimipramineTrimipramine may increase the sedative activities of Pramipexole.Approved
TriprolidineTriprolidine may increase the sedative activities of Pramipexole.Approved
Uc1010Uc1010 may increase the sedative activities of Pramipexole.Investigational
Valproic AcidValproic Acid may increase the sedative activities of Pramipexole.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pramipexole.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Pramipexole.Approved
VigabatrinVigabatrin may increase the sedative activities of Pramipexole.Approved
VortioxetineVortioxetine may increase the sedative activities of Pramipexole.Approved
XylazineXylazine may increase the sedative activities of Pramipexole.Vet Approved
ZaleplonZaleplon may increase the sedative activities of Pramipexole.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the sedative activities of Pramipexole.Approved
ZiprasidoneZiprasidone may increase the sedative activities of Pramipexole.Approved
ZolazepamZolazepam may increase the sedative activities of Pramipexole.Vet Approved
ZolpidemZolpidem may increase the sedative activities of Pramipexole.Approved
ZonisamideZonisamide may increase the sedative activities of Pramipexole.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Pramipexole.Approved
ZotepineZotepine may increase the sedative activities of Pramipexole.Approved
ZuclopenthixolZuclopenthixol may increase the sedative activities of Pramipexole.Approved, Investigational
Food Interactions
  • Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.
References
Synthesis Reference

DrugSyn.org

US4886812
General References
  1. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [PubMed:7664822 ]
External Links
ATC CodesN04BC05
AHFS Codes
  • 28:36.20.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.9631
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.6384
P-glycoprotein inhibitor INon-inhibitor0.842
P-glycoprotein inhibitor IINon-inhibitor0.7464
Renal organic cation transporterNon-inhibitor0.6788
CYP450 2C9 substrateNon-substrate0.8524
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9179
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorInhibitor0.5364
CYP450 2C19 inhibitorInhibitor0.586
CYP450 3A4 inhibitorNon-inhibitor0.6708
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7797
Ames testNon AMES toxic0.8133
CarcinogenicityNon-carcinogens0.915
BiodegradationNot ready biodegradable0.9255
Rat acute toxicity2.8676 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8732
hERG inhibition (predictor II)Non-inhibitor0.8397
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral0.75 mg
TabletOral0.125 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1.0 mg
TabletOral1.5 mg
Tablet, extended releaseOral.375 mg/1
Tablet, extended releaseOral.75 mg/1
Tablet, extended releaseOral1.5 mg/1
Tablet, extended releaseOral2.25 mg/1
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral3.75 mg/1
Tablet, extended releaseOral4.5 mg/1
TabletOral0.088 mg
TabletOral0.18 mg
TabletOral0.35 mg
TabletOral0.7 mg
TabletOral1.1 mg
Tablet, extended releaseOral0.26 mg
Tablet, extended releaseOral0.52 mg
Tablet, extended releaseOral1.05 mg
Tablet, extended releaseOral1.57 mg
Tablet, extended releaseOral2.1 mg
Tablet, extended releaseOral2.62 mg
Tablet, extended releaseOral3.15 mg
TabletOral0.50 mg
TabletOral1 mg
TabletOral.125 mg/1
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral.75 mg/1
TabletOral1 mg/1
TabletOral1.5 mg/1
Prices
Unit descriptionCostUnit
Mirapex er 0.375 mg tablet9.83USD tablet
Mirapex er 0.75 mg tablet9.83USD tablet
Mirapex er 1.5 mg tablet9.83USD tablet
Mirapex er 3 mg tablet9.83USD tablet
Mirapex er 4.5 mg tablet9.83USD tablet
Mirapex 0.125 mg tablet3.48USD tablet
Mirapex 0.25 mg tablet3.42USD tablet
Mirapex 0.5 mg tablet3.42USD tablet
Mirapex 1 mg tablet3.42USD tablet
Mirapex 1.5 mg tablet3.42USD tablet
Mirapex 0.75 mg tablet3.28USD tablet
Pramipexole Dihydrochloride 0.125 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.25 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 0.5 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1 mg tablet3.07USD tablet
Pramipexole Dihydrochloride 1.5 mg tablet3.07USD tablet
Pramipexole di-hcl 0.125 mg tablet2.95USD tablet
Pramipexole di-hcl 0.25 mg tablet2.95USD tablet
Pramipexole di-hcl 0.5 mg tablet2.95USD tablet
Pramipexole di-hcl 1 mg tablet2.95USD tablet
Pramipexole di-hcl 1.5 mg tablet2.95USD tablet
Mirapex 1 mg Tablet2.2USD tablet
Mirapex 1.5 mg Tablet2.2USD tablet
Apo-Pramipexole 1 mg Tablet1.23USD tablet
Apo-Pramipexole 1.5 mg Tablet1.23USD tablet
Co Pramipexole 1 mg Tablet1.23USD tablet
Co Pramipexole 1.5 mg Tablet1.23USD tablet
Novo-Pramipexole 1 mg Tablet1.23USD tablet
Novo-Pramipexole 1.5 mg Tablet1.23USD tablet
Pms-Pramipexole 1 mg Tablet1.23USD tablet
Pms-Pramipexole 1.5 mg Tablet1.23USD tablet
Sandoz Pramipexole 1 mg Tablet1.23USD tablet
Sandoz Pramipexole 1.5 mg Tablet1.23USD tablet
Mirapex 0.25 mg Tablet1.1USD tablet
Apo-Pramipexole 0.25 mg Tablet0.62USD tablet
Co Pramipexole 0.25 mg Tablet0.62USD tablet
Novo-Pramipexole 0.25 mg Tablet0.62USD tablet
Pms-Pramipexole 0.25 mg Tablet0.62USD tablet
Sandoz Pramipexole 0.25 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2275379 No2006-11-282018-01-16Canada
US4886812 No1993-10-082010-10-08Us
US6001861 No1998-01-162018-01-16Us
US6194445 No1998-01-162018-01-16Us
US7695734 No2008-04-262028-04-26Us
US8679533 No2009-09-082029-09-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.14 mg/mLALOGPS
logP2.18ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)17.66ChemAxon
pKa (Strongest Basic)10.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.94 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.77 m3·mol-1ChemAxon
Polarizability24.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Primary amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I: Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005 Apr;33(4):495-9. Epub 2005 Jan 7. [PubMed:15640376 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 06, 2016 02:41